Search

everythinglearnresearchcommunity

for

Search:↓

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.

Blocking specific proteins can help remove aging cells and might treat age-related diseases and promote hair growth.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

Seven new genetic risk areas for prostate cancer were found.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

PROTACs show promise for cancer treatment, but designing them effectively is challenging.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

LGD1069 effectively prevents breast tumors in mice without toxicity.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Mutations in the KRT16 gene can cause skin and nail disorders.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

KRT14 gene variants cause dermatopathia pigmentosa reticularis, affecting nails, teeth, and hair.

The protein CCN2 controls hair growth by affecting hair follicle formation and stem cell activity in mice.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

β-catenin helps hair follicle stem cells grow by activating a specific cell pathway.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

A new gene location for Keratosis follicularis squamosa was found on chromosome 7p14.3-7p12.1.

Putting thymidine dinucleotide on newborn mice's skin can delay and reduce skin cancer.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.